Metabolomics in dyslipidemia

Area of Science:

• Biochemistry
• Metabolomics
• Cardiovascular Disease Research

Background:

• Hyperlipidemia poses a significant global health challenge, with current biomarkers lacking early diagnostic sensitivity.
• Existing clinical markers for hyperlipidemia (triglyceride, total cholesterol, LDL, HDL) often show changes only in advanced stages of the disease.

Purpose of the Study:

• To review the application of metabolomics in identifying novel, sensitive biomarkers for early hyperlipidemia detection.
• To explore the potential of metabolomics for understanding the pathophysiologic mechanisms of hyperlipidemia.
• To summarize analytical techniques, data handling, and findings from metabolomic studies in hyperlipidemia.

Main Methods:

• Review of analytical techniques in untargeted metabolomics.
• Analysis of data collection and processing strategies for metabolomic studies.
• Synthesis of findings from metabolomics research in hyperlipidemia animal models and human clinical studies.

Main Results:

• Metabolomics provides a comprehensive metabolic profile, offering potential for improved diagnostic accuracy in hyperlipidemia.
• This approach can reveal underlying pathophysiologic mechanisms of hyperlipidemia beyond traditional markers.
• The review covers hypolipemia mechanisms and discusses antilipemic drug therapies.

Conclusions:

• Metabolomics presents a promising avenue for discovering sensitive biomarkers for early hyperlipidemia diagnosis and management.
• This holistic approach enhances understanding of hyperlipidemia's complex metabolic underpinnings.
• Further research integrating metabolomic insights can advance clinical practice for hyperlipidemia treatment.